The Lancet Commission recently published worrying data: almost half of the global population has no access to basic medical diagnostics. In low-income countries, the figure is more than 80 percent.

The Commission advocates scalable solutions that are also effective outside of highly developed clinics. This is where our epigenetic tests come into play.

Our WID® test family includes epigenetic tests that detect DNA methylation and indicate cancer.

The WID®-easy Test enables early risk stratification in women with abnormal uterine bleeding, with the aim of detecting endometrial cancer at an early stage. Currently, the sample is taken by a healthcare professional and the analysis is then carried out in a laboratory.

In future, however, the WID®-easy Test could also be used on self-collected samples and thus represent an additional low-threshold option. Especially in regions without comprehensive cervical cancer screening, it is of great importance that the WID®-easy Test detects not only endometrial but also cervical carcinoma – as both cancers only become symptomatic through abnormal bleeding.

The Lancet Commission and the newly founded Global Diagnostics Coalition are calling for innovations that can reach people in underserved regions. Technologies such as the WID®-easy Test and the other products in the WID® test family fit exactly into this framework: they are suitable for standardized risk stratification programs and could also enable decentralized sampling in the long term.

Our goal is to further develop the WID® test family – with a clear focus on broad-based objective application, without any loss of quality. At Sola Diagnostics, we are currently not a member of the Coalition, but we see it as our responsibility as an innovative company to actively work on solutions with international relevance.

We are currently working on further developing our epigenetic tests towards even broader clinical coverage, with the aim of reliably detecting and predicting the development of as many relevant gynaecological tumor types as possible. At the same time, we are evaluating ways in which WID® tests can be integrated into national screening programmes and decentralised screening structures.

Compared to other diagnostic procedures such as cytology or mammography, which are based on subjective interpretation, WID® tests are objectively evaluable procedures whose interpretation does not require any special professional expertise. They can therefore be used on a wide scale – even without long-term training or cost-intensive equipment.

Our vision is clear: early detection of cancer should not be a privilege for well-equipped health systems. With the right technology, prevention can be redesigned to be accessible, reliable, and precise. The WID-easy® test is objective, easy to perform and requires only a real-time PCR device, used widely for Covid testing, and no special training or experience.

For further information, please refer to the full report of the Lancet Commission.